Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
December 8, 2025BloodOpen Access

RUNX1 mutations define a high-risk biological subset of chronic myelomonocytic leukemia and cooperate with ASXL1 mutations to drive leukemic transformation

View Full Paper
Ask AI
Bookmark
Share

Authors

SLSanam LoghaviÁBÁlex BatallerRKRashmi Kanagal‐Shamanna

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows RUNX1 mutations worsen outcomes in chronic myelomonocytic leukemia, suggesting the need for targeted therapies.

Key Points

  • RUNX1 mutations are linked to a higher risk of developing acute myeloid leukemia in chronic myelomonocytic leukemia patients.
  • Among 370 patients, 20% had RUNX1 mutations, leading to lower hemoglobin levels compared to those without mutations.
  • Next generation sequencing revealed various mutations, highlighting the role of hypomethylating agents in treatment.
  • The presence of RUNX1 mutations significantly reduces leukemia-free survival and overall survival rates in patients.

Cite This Study

Loghavi et al. (2025) studied this question.

synapsesocial.com/papers/69362f4e4fa91c937236d850https://doi.org/10.1182/blood-2025-3857
View Full Paper
Ask AI
Bookmark
Share